Back to today’s briefing

Story perspectives

New Breast Cancer Vaccine Shows Promise in Phase 1 Trials

12/12/2025

46 5 Full Breakdown

Summary

Story summary

Cleveland Clinic researchers presented Phase 1 results of a vaccine targeting ?-lactalbumin to prevent triple-negative breast cancer at San Antonio Breast Cancer Symposium.
In 35 women, 74% developed an immune response and the vaccine showed only mild side effects.
Dr. G. Thomas Budd of Cleveland Clinic says the results are encouraging, but Phase 1 did not measure clinical effectiveness; Phase 2 is planned for late next year to reduce recurrence.

1 of 1

Story summary

Cleveland Clinic researchers presented Phase 1 results of a vaccine targeting ?-lactalbumin to prevent triple-negative breast cancer at San Antonio Breast Cancer Symposium.
In 35 women, 74% developed an immune response and the vaccine showed only mild side effects.
Dr. G. Thomas Budd of Cleveland Clinic says the results are encouraging, but Phase 1 did not measure clinical effectiveness; Phase 2 is planned for late next year to reduce recurrence.